BrainStorm Cell Therapeutics, Inc. (BCLI.OB) Receives Funding for ALS Research

QualityStocks would like to highlight BrainStorm Cell Therapeutics, Inc. (OTCBB: BCLI). BrainStorm is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University.

In the company’s news yesterday,

BrainStorm Cell Therapeutics Inc. announced that it has secured the necessary funding to complete pre-clinical trials for treatments of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The funding includes a prestigious grant from the Israeli government’s Office of the Chief Scientist (OCS) as well as a private investment.

CEO of BrainStorm, Rami Efrati, stated, “We are very gratified to receive these financial votes of confidence in our breakthrough stem cell technology. The new funding will enable us to complete our pre-clinical studies in ALS and meet our goal of beginning clinical studies in the coming year.”

The non-equity OCS grant totals $450,000 and marks the third consecutive year BrainStorm has received the award. Previously, the company received OCS grants totaling $798,000. BrainStorm’s royalty obligations to the OCS are capped at the amount of the grant received from the OCS.

Additionally, ACCBT Corporation, a private company that invests in biotechnology, announced that it will give an additional investment of about $1 million in BrainStorm. The new funding will comprise monthly tranches of $50,000 or more. ACCBT, under the control of BrainStorm’s president Chaim Lebovits, has previously invested more than $4 million in the company. ACCBT will receive shares of common stock from the company at a price of $0.12 per share and warrants for $0.29.

Mr. Lebovits commented, “The promising study results we have seen so far make me confident that the company, with G-D’s help, will be able to rapidly progress to a therapy for the unmet medical need of devastating neurodegenerative conditions like ALS.”

The company expects to begin Phase I clinical studies in 2010.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.